8-K: Phathom Pharmaceuticals Stockholders Re-Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

Phathom Pharmaceuticals, Inc. announced the results of its 2025 Annual Meeting of Stockholders, confirming the re-election of two Class III directors, the ratification of Ernst & Young LLP as its independent auditor, and advisory approval of executive compensation.

Summary

• At the 2025 Annual Meeting of Stockholders held on June 3, 2025, Phathom Pharmaceuticals, Inc. stockholders voted on four key proposals.
• Heidi Kunz was re-elected as a Class III director with 34,023,182 votes For and 451,384 Withheld.
• James Topper, M.D., Ph.D. was re-elected as a Class III director with 26,884,171 votes For and 7,590,395 Withheld.
• Both elected directors will serve a three-year term expiring at the Company's 2028 Annual Meeting of Stockholders.
• Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2025 with 51,670,346 votes For, 177,785 Against, and 53,817 Abstentions.
• The compensation of the named executive officers was approved on a non-binding, advisory basis (say-on-pay) with 24,584,781 votes For, 8,704,739 Against, and 1,185,046 Abstentions.
• Stockholders approved, on a non-binding, advisory basis, the frequency of future votes on executive compensation to be held every 1 year, with 30,665,967 votes for 1 Year, significantly outweighing votes for 2 or 3 years.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as all proposals passed, indicating shareholder support for the company's governance and management. The strong preference for annual say-on-pay votes aligns with best practices. The only minor negative is the notable 'Against' votes for executive compensation, but it did not prevent approval.

Positives

• All proposals presented at the Annual Meeting were approved by the stockholders, indicating general alignment with the Board's recommendations.
• The re-election of both Class III directors, Heidi Kunz and James Topper, M.D., Ph.D., ensures continuity in the Board's composition.
• The overwhelming ratification of Ernst & Young LLP as the independent auditor for fiscal 2025 demonstrates strong confidence in the Company's financial oversight.
• Stockholders' preference for annual 'say-on-pay' votes aligns with best practices in corporate governance and the Board's recommendation, promoting regular accountability for executive compensation.

Negatives

• While the 'say-on-pay' proposal passed, a notable percentage of votes (approximately 26% of votes cast, excluding broker non-votes) were cast Against the compensation of named executive officers, suggesting some shareholder dissent on this matter.

Future Outlook

The Company intends to hold future advisory stockholder votes on the compensation of its named executive officers annually, consistent with the Board's recommendation and the results of the non-binding advisory vote, and will include these votes in its proxy materials for each annual meeting until the next required vote on Say-On-Frequency.

Management Comments

• "Consistent with the recommendation of the Company's Board of Director, as set forth in the 2025 Proxy Statement, and based on the results of this non-binding advisory vote, it is the Company's intent that future advisory stockholder votes on the compensation of its named executive officers will be held annually and included in the Company's proxy materials for each annual meeting until the next required vote on Say-On-Frequency."

Industry Context

This filing represents a routine annual corporate governance event for a publicly traded pharmaceutical company, reflecting standard practices for stockholder engagement and oversight of board composition, auditing, and executive compensation.

Comparison to Industry Standards

• The re-election of directors and ratification of auditors are standard practices for public companies, aligning with typical corporate governance frameworks.
• The advisory 'say-on-pay' vote and 'say-on-frequency' vote are common requirements for U.S. public companies, reflecting broader trends in shareholder activism and executive compensation transparency.
• The strong preference for annual 'say-on-pay' votes aligns with a growing trend among institutional investors and proxy advisory firms who advocate for more frequent shareholder input on executive compensation, often seen in companies like Pfizer, Merck, or Johnson & Johnson.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The re-election of directors and approval of proposals indicate stability in governance and alignment with shareholder preferences on key matters like executive compensation frequency.
• Management: The advisory approval of executive compensation, despite some dissent, allows the current compensation structure to continue, while the annual frequency of future votes increases accountability.
• Employees: No direct impact mentioned, but stable governance can contribute to a stable work environment.
• Auditors: Ernst & Young LLP's re-appointment ensures continuity in the auditing relationship.

Next Steps

• Future advisory stockholder votes on the compensation of named executive officers will be held annually and included in the Company's proxy materials for each annual meeting until the next required vote on Say-On-Frequency.

Key Dates

Keywords

Phathom Pharmaceuticals, Annual Meeting, Stockholder Vote, Corporate Governance, SEC Filing, 8-K, Director Election, Auditor Ratification, Executive Compensation, Say-on-Pay, Proxy Statement, PHAT